Locations & Facilities

State-of-the-art facility, encompassing 200,000 sq. ft., has been operational since 2018.

Site offers comprehensive, integrated one-stop biologics CMC development and GMP manufacturing services in one central location.

Facility houses 10 European Medicines Agency (EMA)-certified GMP cell banking suites.

1.6 million sq. ft. global innovation site to be operational in 2021

New state-of-the-art facilities providing discovery, development, analytical development and QC testing and pilot and clinical-scale GMP manufacturing capabilities in one location

Multiple facilities with a total area of 160,000 sq. m.

Early and late-stage development laboratories and clinical and commercial-scale drug substance and drug product GMP manufacturing

First facility in China approved by the U.S. FDA and EMA for production of a commercial antibody therapeutic

Facility dedicated to the development and GMP manufacture of Antibody Drug Conjugates (ADCs) and other bioconjugates. Facility footprint encompasses nearly 6,000 square meters.

Site provides integrated services and solutions including process development, technology transfer, and pilot scale to large-scale cGMP production of drug substance and drug product.

State-of-the-art facility houses an advanced, fully-isolated automatic aseptic filling system which can fill 2R, 6R, 10R, 20R and 50R vials for either liquid or lyophilized products. With ability to provide three million doses annually, system provides the flexibility to meet production requirements for both global clinical trials and commercial product launch.

Site is part of WuXi XDC, a WuXi Biologics subsidary, that offers extensive and comprehensive set of in-house capabilities to handle all stages of ADC drug development, including development and manufacture of payload-linkers and antibody or other biological intermediates.

Site opened in December 2014

Over 10,100 sq. m. testing facility was the first non-government affiliated biosafety testing facility in Asia

Facility performs cell line characterization, viral clearance validation studies and unprocessed bulk lot release

Acquired CMAB Biopharma Group to build MFG21 and DP11

Cell line engineering and process development laboratories

Drug substance capacity: 7,000L

Liquid and lyophilization drug product fills available

Operational since 2020 this multi-facility site will be GMP-ready in 2021

Home to facilities dedicated to the development and GMP manufacture of recombinant proteins and plasmid DNA produced via microbial fermentation

Separate facilities available for the development and GMP production of viral-based vaccines

50,000 sq. m. facility, operational since 2018 available for GMP Production in H2 2021

Acquired site as well as its labor force from Pfizer China (“Pfizer”) in March 2021. 

Drug substance capacities: 2 x 2,000L and expandable to 4 x 2,000L

Liquid or lyophilized drug product fills into vials and pre-filled syringes at 10 million units/year and 1 x 10m² lyo capacity

Planned to open in 2023 this 314,000 sq. m. (1.3 million sq. ft.) multi-facility site will be the largest CDMO site in western China

New integrated manufacturing center will include drug research and development and commercial-scale drug substance manufacturing facilities with initial bioreactor capacity of 48,000 L

Planned 82,160 sq. m. facility will be one of the largest CDMO facilities in northern China 

New biologics center will house development laboratories and a biologics commercial-scale drug substance manufacturing facility with initial bioreactor capacity of 48,000 L

Operations to commence in 2022

Invested $60 Million to provide facilities for early stage bioprocess development and clinical-scale GMP manufacture

Operations expected to commence in 2023